| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Fraxinol targets cytochrome P450 enzymes. It modulates NF-κB and MAPK signaling pathways. By inhibiting NF-κB, it reduces inflammation. It scavenges reactive oxygen species, reducing oxidative stress. Its anticancer effects are mediated through the induction of apoptosis in tumor cells.
|
|---|---|
| ln Vitro |
In vitro, fraxinol has antioxidant, anti-inflammatory, and anticancer activities. It scavenges reactive oxygen species. It inhibits NF-κB and MAPK signaling. It induces apoptosis in tumor cells. It has hepatoprotective effects. Its activity against cytochrome P450 enzymes has been characterized.
|
| ln Vivo |
In vivo, fraxinol has demonstrated hepatoprotective, anti-inflammatory, and anticancer effects. Its antioxidant properties contribute to its protective effects in models of oxidative stress. Its anti-inflammatory effects have been observed in animal models. Its anticancer activity is being investigated.
|
| Enzyme Assay |
In vitro enzyme assays for fraxinol measure its effects on cytochrome P450 enzymes. The compound is incubated with the enzyme and a substrate, and the reaction is monitored by HPLC. Its antioxidant activity is assessed using standard cell-free assays such as DPPH and ABTS.
|
| Cell Assay |
In vitro cell-based assays for fraxinol involve treating cells with the compound and measuring its effects on cell viability, apoptosis, and inflammation. Its effects on NF-κB and MAPK signaling are assessed by Western blotting. Its antioxidant effects are measured by assessing reactive oxygen species levels.
|
| Animal Protocol |
In vivo animal experiments for fraxinol have been conducted in models of liver injury and inflammation. Animals are treated with fraxinol, and its hepatoprotective and anti-inflammatory effects are assessed by measuring serum markers and tissue histology.
|
| ADME/Pharmacokinetics |
Fraxinol has a molecular weight of 222.19 and a molecular formula of C11H10O5. It has a density of 1.4±0.1 g/cm3 and a boiling point of 449.7±45.0 °C. It is soluble in DMSO (60 mg/mL). Its purity is typically >98%.
|
| Toxicity/Toxicokinetics |
Fraxinol is a natural compound and is generally considered to have a favorable safety profile. It is for research use only and is not intended for human use. Standard safety precautions should be taken when handling.
|
| References | |
| Additional Infomation |
Fraxinol is a hydroxycoumarin. It has been reported to exist in Elsholtzia bodinieri, Prunus prostrata, and other organisms with relevant data.
Fraxinol is a natural coumarin compound. It has antioxidant, anti-inflammatory, hepatoprotective, and anticancer effects. It targets cytochrome P450 enzymes and modulates NF-κB and MAPK signaling. It induces apoptosis in tumor cells. It is also known as 5,7-dimethoxy-6-hydroxycoumarin. |
| Molecular Formula |
C11H10O5
|
|---|---|
| Molecular Weight |
222.1941
|
| Exact Mass |
222.052
|
| CAS # |
486-28-2
|
| PubChem CID |
3047739
|
| Appearance |
Light yellow to yellow solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
449.7±45.0 °C at 760 mmHg
|
| Melting Point |
170-172ºC
|
| Flash Point |
182.1±22.2 °C
|
| Vapour Pressure |
0.0±1.1 mmHg at 25°C
|
| Index of Refraction |
1.588
|
| LogP |
0.9
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
16
|
| Complexity |
301
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
PBPNOAHYDPHKFH-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C11H10O5/c1-14-8-5-7-6(3-4-9(12)16-7)11(15-2)10(8)13/h3-5,13H,1-2H3
|
| Chemical Name |
6-hydroxy-5,7-dimethoxychromen-2-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~25 mg/mL (~112.52 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (11.25 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (11.25 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (11.25 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.5007 mL | 22.5033 mL | 45.0065 mL | |
| 5 mM | 0.9001 mL | 4.5007 mL | 9.0013 mL | |
| 10 mM | 0.4501 mL | 2.2503 mL | 4.5007 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
